Viridian Therapeutics, Inc. announced on September 8, 2023, Kristian Humer, the Chief Business Officer of the company resigned, effective September 12, 2023. on September 12, 2023, Seth Harmon, the Company?s Senior Vice President of Finance, assumed the role of the Company?s principal financial and accounting officer. Mr. Harmon, age 44, joined the Company in May 2023.

Prior to joining the Company, from May 2020 to May 2023, Mr. Harmon served as the Chief Financial Officer and Vice President of Finance and Administration for the U.S. subsidiary of BioNTech SE, a biotechnology company, where he oversaw the general and administrative functions for BioNTech SE?s US subsidiary and served as a member of the BioNTech US management team. Prior to BioNTech US, he was the Vice President of Finance and Accounting at Neon Therapeutics, Inc., a biotechnology company, where he served from April 2017 to May 2020. From July 2014 to April 2017, he served as Controller at Merrimack Pharmaceuticals, Inc., a biopharmaceutical company.

Prior to that, Mr. Harmon held several roles of increasing responsibility at Ernst & Young LLP where he obtained his certified public accountant license. Mr. Harmon holds an M.S. in Accounting and Business from Northeastern University and a B.A. in Economics and Mathematics from Bowdoin College.